Related Experiment Videos
The problems of treating atypical pneumonia
1II. Chirurgische Universitatsklinik, Wien, Austria.
The Journal of Antimicrobial Chemotherapy
|March 1, 1993
Summary
Atypical pneumonia, caused by various pathogens like Chlamydia pneumoniae, requires specific antibiotic treatment. Newer macrolides offer improved efficacy and dosing for these infections.
Area of Science:
- Infectious Diseases
- Pulmonology
- Microbiology
Background:
- Atypical pneumonia presents with a milder clinical course than typical bacterial pneumonia.
- It is caused by diverse pathogens including Mycoplasma pneumoniae, chlamydiae (notably Chlamydia pneumoniae TWAR-strain), rickettsiae, viruses, and Legionella pneumophila.
Purpose of the Study:
- To review the causative agents of atypical pneumonia.
- To discuss current and alternative therapeutic strategies for atypical pneumonia.
- To highlight the role of newer antibiotics.
Main Methods:
- Literature review of atypical pneumonia pathogens and treatment guidelines.
- Analysis of treatment efficacy for various causative agents.
- Comparison of antibiotic properties and patient outcomes.
Main Results:
- Chlamydia pneumoniae (TWAR-strain) is a significant cause of community-acquired pneumonia.
- Empirical treatment for typical pneumonia often fails for atypical cases.
- Erythromycin and tetracyclines are standard treatments, with tetracyclines preferred for Coxiella and psittacosis.
- Legionella pneumonia treatment involves erythromycin or alternatives like tetracyclines or quinolones.
- Newer macrolides show promise due to improved pharmacokinetic profiles, including once-daily dosing and high tissue concentrations.
Conclusions:
- Accurate diagnosis of atypical pneumonia is crucial for effective treatment.
- Antibiotic selection must be tailored to the specific pathogen.
- Newer macrolide antibiotics represent a promising advancement in treating atypical pneumonia caused by Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae.